Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK14 | O94921 | 2/20 | 0.46 |
| ▸ | CCNY | Q8ND76 | 2/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 4/20 | 0.43 |
| ▸ | EGFR | P00533 | 8/20 | 0.43 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.41 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 4/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.40 |
| ▸ | CDK7 | P50613 | 1/20 | 0.39 |
| ▸ | CCNH | P51946 | 1/20 | 0.39 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21481530 | 0.86 | CDK14 (0.50) | CDK14CCNYACKR3BTKPIP4K2A | |
| SCHEMBL21481478 | 0.84 | EGFR (0.51) | BTKEGFRITKBRD4JAK3 | |
| SCHEMBL21481476 | 0.82 | ACKR3 (0.47) | CDK14CCNYACKR3BTKEGFR | |
| SCHEMBL23352056 | 0.82 | BRD4 (0.46) | BRD4 | |
| SCHEMBL28421375 | 0.76 | CDK14 (0.57) | CDK14CCNYBTKPIP4K2APIP4K2B | |
| SCHEMBL21282758 | 0.76 | CDK14 (0.57) | CDK14CCNYBTKPIP4K2APIP4K2B | |
| SCHEMBL27812229 | 0.75 | MAPK14 (0.49) | — | |
| SCHEMBL29289884 | 0.74 | BRD4 (0.53) | BRD4AURKARPS6KB1 | |
| SCHEMBL21481482 | 0.74 | GLS (0.46) | BRD4 | |
| SCHEMBL12908113 | 0.74 | MMP13 (0.46) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | QURIENT CO., LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-20210139483-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2021-05-13 | — | — | US | disclosed |
| WO-2019197546-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES | QURIENT CO., LTD. (KR) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | CDKL5, CDK15, CDK5 | CDK14 26/4885CCNY 46/4885ACKR3 2216/4885 |
| US-20210139483-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES | IL5, THPO, TYMP | CDK14 577/4885CCNY 597/4885ACKR3 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.